David Bergman1,2, Mark S Clements1, Hamed Khalili3,4, Lars Agréus5, Rolf Hultcrantz6,7, Jonas F Ludvigsson1,8. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 2. Brommaplans Primary Health Care Center, Stockholm, Sweden. 3. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts. 4. Harvard Medical School, Boston, Massachusetts. 5. Division for Family Medicine and Primary Care, Karolinska Institutet, Huddinge, Sweden. 6. Unit of Hepatology, Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden. 7. Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 8. Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.
Abstract
BACKGROUND: Epidemiological studies of microscopic colitis have shown varying but increasing incidence rates. AIM: To assess the incidence of microscopic colitis in Sweden. METHODS: Nationwide cohort study performed in 1995-2015 based on biopsy reports. Age-specific and age-standardised incidence rates were calculated. RESULTS: We identified 13 844 patients with an incident diagnosis of microscopic colitis. Lymphocytic colitis (n = 9238) constituted 67% and collagenous colitis (n = 4606) 33% of microscopic colitis. The mean age at time of diagnosis of microscopic colitis was 60.2 years (58.6 for lymphocytic colitis, 63.3 for collagenous colitis). The lifetime risk of developing microscopic colitis was 0.87% in women (95% confidence interval, CI: 0.85-0.88) and 0.35% in men (95% CI: 0.34-0.36). From 2006, the overall incidence of microscopic colitis was approximately 10.5 cases per 100 000 person-years (95% CI: 9.8-11.3) with higher rates in women (72% of cases, incidence rate ratio = 2.4 (95% CI: 2.3-2.5) and the elderly with increasing rates up to 75-79 years. From 2006-2015, there was a significant increase of 1% per year (P = 0.02) in the overall microscopic colitis incidence rate in women; the estimated annual percent change was similar, although not statistically significant, in men (P = 0.15). CONCLUSIONS: In Sweden, the incidence of microscopic colitis is still increasing in women, although the rate appears to be stabilising. The incidence is particularly high in women and the elderly up to age 75-79 years. Finally, across a lifetime, 1 in 115 females and 1 in 286 males are expected to be diagnosed with microscopic colitis and thus posing a considerable disease burden.
BACKGROUND: Epidemiological studies of microscopic colitis have shown varying but increasing incidence rates. AIM: To assess the incidence of microscopic colitis in Sweden. METHODS: Nationwide cohort study performed in 1995-2015 based on biopsy reports. Age-specific and age-standardised incidence rates were calculated. RESULTS: We identified 13 844 patients with an incident diagnosis of microscopic colitis. Lymphocytic colitis (n = 9238) constituted 67% and collagenous colitis (n = 4606) 33% of microscopic colitis. The mean age at time of diagnosis of microscopic colitis was 60.2 years (58.6 for lymphocytic colitis, 63.3 for collagenous colitis). The lifetime risk of developing microscopic colitis was 0.87% in women (95% confidence interval, CI: 0.85-0.88) and 0.35% in men (95% CI: 0.34-0.36). From 2006, the overall incidence of microscopic colitis was approximately 10.5 cases per 100 000 person-years (95% CI: 9.8-11.3) with higher rates in women (72% of cases, incidence rate ratio = 2.4 (95% CI: 2.3-2.5) and the elderly with increasing rates up to 75-79 years. From 2006-2015, there was a significant increase of 1% per year (P = 0.02) in the overall microscopic colitis incidence rate in women; the estimated annual percent change was similar, although not statistically significant, in men (P = 0.15). CONCLUSIONS: In Sweden, the incidence of microscopic colitis is still increasing in women, although the rate appears to be stabilising. The incidence is particularly high in women and the elderly up to age 75-79 years. Finally, across a lifetime, 1 in 115 females and 1 in 286 males are expected to be diagnosed with microscopic colitis and thus posing a considerable disease burden.
Authors: Blake Niccum; Kevin Casey; Kristin Burke; Emily W Lopes; Paul Lochhead; Ashwin Ananthakrishnan; James M Richter; Jonas F Ludvigsson; Andrew T Chan; Hamed Khalili Journal: Inflamm Bowel Dis Date: 2022-08-01 Impact factor: 7.290
Authors: Hamed Khalili; Jordan E Axelrad; Bjorn Roelstraete; Ola Olén; Mauro D'Amato; Jonas F Ludvigsson Journal: Gastroenterology Date: 2021-01-06 Impact factor: 22.682
Authors: Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch Journal: United European Gastroenterol J Date: 2021-02-22 Impact factor: 4.623
Authors: June Tome; Kanika Sehgal; Amrit K Kamboj; William S Harmsen; Patricia P Kammer; Edward V Loftus; William J Tremaine; Sahil Khanna; Darrell S Pardi Journal: Clin Gastroenterol Hepatol Date: 2021-06-30 Impact factor: 13.576
Authors: Robert S Sandler; Temitope O Keku; John T Woosley; Dale P Sandler; Joseph A Galanko; Anne F Peery Journal: World J Gastroenterol Date: 2022-01-14 Impact factor: 5.742